Similarly, a higher risk of disease recurrence was seen in patients with metastatic HER2+ BC harboring PIK3CA gene alteration in the EMILIA and CLEOPATRA trials, despite the dual HER2 blockage [166,167]. Here, PIK3CA is linked to breast cancer.